

## Instructions to Authors

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

**Tables.** Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

**References.** Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Submission of Manuscripts.* Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios

International Institute of Anticancer Research (IIAR)

Editorial Office of ANTICANCER RESEARCH,

IN VIVO, CANCER GENOMICS and PROTEOMICS.

1st km Kapandritiou-Kalamou Road

P.O. Box 22, GR-19014 Kapandriti, Attiki

GREECE

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

*Reprints.* Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2011 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.



- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

## General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

## Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iiarjournals.org](http://www.iiarjournals.org)

## Selection of Recent Articles

Animal Models of *N*-Methyl-*N*-nitrosourea-induced Mammary Cancer and Retinal Degeneration with Special Emphasis on Therapeutic Trials. A. TSUBURA, Y.-C. LAI, H. MIKI, T. SASAKI, N. UEHARA, T. YURI, K. YOSHIZAWA (*Osaka, Japan*)

Intraesophageal Administration of GS-Nitroxide (JP4-039) Protects Against Ionizing Irradiation-induced Esophagitis. M.W. EPPERLY, J.P. GOFF, S. LI, X. GAO, P. WIPF, T. DIXON, H. WANG, D. FRANICOLA, H. SHEN, J.-C.M. RWIGEMA, V. KAGAN, M. BERNARD, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Effects of Combined Insulin-like Growth Factor 1 and Macrophage Colony-stimulating Factor on the Skeletal Properties of Mice. S.A. LLOYD, S.J. SIMSKE, L.K. BOGREN, S.E. OLESIAK, T.A. BATEMAN, V.L. FERGUSON (*Hershey, PA; Boulder; Fort Collins, CO; Chapel Hill, NC, USA*)

Cell Death Detection after High-LET Irradiation in an Orthotopic Human Hepatocellular Carcinoma *in Vivo*. A. ALTMAYER, M. IGNAT, J.-M. DENIS, N. MESSADDEQ, J. GUEULETTE, D. MUTTER, P. BISCHOFF (*Strasbourg; Illkirch Graffenstaden, France; Brussels, Belgium*)

Serum Calcium-decreasing Factor, Caldecrin, Ameliorates Muscular Dystrophy in dy/dy Mice. M. TOMOMURA, T. FUJII, H. SAKAGAMI, A. TOMOMURA (*Saitama; Tokushima, Japan*)

Nitric Oxide Concentrations are Normal and Unrelated to Activity Level in Chronic Fatigue Syndrome. M. MEEUS, I. VAN EUPEN, J. HONDEQUIN, L. DE HAUWERE, D. KOS, J. NIJS (*Antwerpen; Brussel, Belgium*)

Gene Expression Analysis of Oxidative Stress and Apoptosis in Proton-irradiated Rat Retina. X.W. MAO, L.M. GREEN, T. MEKONNEN, N. LINDSEY, D.S. GRIDLEY (*Loma Linda, CA, USA*)

Colon Cancer Vaccines: An Update. E. MERIKA, M.W. SAIF, A. KATZ, K. SYRIGOS, M. MORSE (*London, UK; Haven, CT; Durham, NC, USA; Athens, Greece*)

Novel Microminipig Model of Atherosclerosis by High Fat and High Cholesterol Diet, Established in Japan. N. MIYOSHI, M. HORIUCHI, Y. INOKUCHI, Y. MIYAMOTO, N. MIURA, S. TOKUNAGA, M. FUJIKI, Y. IZUMI, H. MIYAJIMA, R. NAGATA, K. MISUMI, T. TAKEUCHI, A. TANIMOTO, N. YASUDA, H. YOSHIDA, H. KAWAGUCHI (*Kagoshima; Osaka, Japan*)

CD95 and TNF $\alpha$ -induced Apoptosis in Liver Metastases of Colorectal Carcinoma. H.-U. KASPER, E. KONZE, M. KERN, D.L. STIPPEL (*Münster; Köln; Heidelberg, Germany*)

Thrombogenicity of Sirolimus-eluting Stents and Bare Metal Stents: Evaluation in the Early Phase after Stent Implantation. T. WALTER, K.S. REY, H.P. WENDEL, S. SZABO, T. SUSELBECK, C.-E. DEMPFLER, M. BORGGREFE, S. SWOBODA, M.E. BEYER, H.M. HOFFMEISTER (*Mannheim; Kirchheim; Tuebingen; Solingen, Germany*)

Non-antibiotics Reverse Resistance of Bacteria to Antibiotics. J.E. KRISTIANSEN, V.F. THOMSEN, A. MARTINS, M. VIVEIROS, L. AMARAL (*Odense; Copenhagen, Denmark; Lisbon, Portugal*)

An Adult Myometrial Pluripotential Precursor that Promotes Healing of Damaged Muscular Tissues. B.G. GALVEZ, N.S. MARTÍN, P. SALAMACOHEN, J.J. LAZCANO, M.J. CORONADO, M.L. LAMELAS, A. ALVAREZ-BARRIENTES, N. EIRÓ, F. VIZOSO, C. RODRIGUEZ (*Gijón, Spain*)

A Possible Mechanism for Altered Immune Response in the Elderly. G. MAZZOCCOLI, A. DE CATA, S. CARUGHI, A. GRECO, M. INGLESE, F. PERFETTO, R. TARQUINI (*San Giovanni Rotondo; Florence, Italy*)

Urine and Serum Analysis of Consumed Curcuminoids Using an IkB-luciferase Surrogate Marker Assay. S. PONNURANGAM, F.G. MONDALEK, J. GOVIND, D. SUBRAMANIAM, C. HOUGHEN, S. ANANT, P. PANTAZIS, R.P. RAMANUJAM (*Oklahoma City, OK, USA*)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

First Surgical Experience of Intraperitoneal Treatment with the Trifunctional Antibody Catumaxomab (Anti-EpCam × Anti-CD3) for Epithelial Ovarian Cancer. G. PAPANIKOLAOU, C. FOTOPOULOU, I. BRAICU, R. CHEKEROV, S.C. SCHMIDT, K. PIETZNER, J. SEHOULI ( <i>Berlin, Germany</i> ) .....	2603
<i>In Vitro</i> Vascular Tube Formation Testing as a Tool for Treatment Individualisation in Patients with Cervical Cancer. S. LANDT, H. HEIDECKE, S. KORLACH, C. REUTER, I. SCHWIDDE, J. BARINOFF, M. THILL, J. SEHOULI, S. KÜMMEL ( <i>Düsseldorf; Luckenwalde; Berlin; Essen; Lübeck, Germany</i> ) .....	2609
Influence of a Dose-dense Adjuvant Chemotherapy on sVCAM-1/sICAM-1 Serum Levels in Breast Cancer Patients with 1-3 Positive Lymph Nodes. H. EGGEMAN, F. STÖBLEN, M. THILL, S. KORLACH, P. SCHMID, D. LÜFTNER, D. ELLING, F.-A. TARAN, S. KÜMMEL, S. LANDT ( <i>Magdeburg; Essen; Lübeck; Berlin; Düsseldorf, Germany; Brighton, UK</i> ) .....	2617
* Review: Cell-free DNA in the Circulation as a Potential Cancer Biomarker. C. KOHLER, Z. BAREKATI, R. RADPOUR, X.Y. ZHONG ( <i>Basel, Switzerland</i> ) .....	2623
Systemic Changes of Tryptophan Catabolites via the Indoleamine-2,3-dioxygenase Pathway in Primary Cervical Cancer. C. FOTOPOULOU, J. SEHOULI, R. PSCHOWSKI, S. VON HAEHLING, G. DOMANSKA, E.-I. BRAICU, G. FUSCH, P. REINKE, J.C. SCHEFOLD ( <i>Berlin; Greifswald, Germany</i> ) .....	2629
Effect of Melatonin on Intra-abdominal Fat in Correlation with Endometrial Proliferation in Ovariectomized Rats. R. CIORTEA, N. COSTIN, I. BRAICU, D. HARAGÂŞ, A. HUDACSKO, C. BONDOR, D. MIHU, C.M. MIHU ( <i>Cluj-Napoca, Romania; Berlin, Germany</i> ) .....	2637
The Utility of an <i>In Vitro</i> Angiogenesis Score for Prognosis Assessment in Patients with Cervical Cancer. S. LANDT, H. HEIDECKE, C. REUTER, S. KORLACH, J.-U. BLOHMER, W. LICHTENEGGER, T. HEUSNER, F. STÖBLEN, M. THILL, J. BARINOFF, J. SEHOULI, S. KÜMMEL ( <i>Düsseldorf; Luckenwalde; Berlin; Essen; Lübeck, Germany</i> ) .....	2645
Prognostic Significance of the Angiogenic Factors Angiogenin, Endoglin and Endostatin in Cervical Cancer. S. LANDT, K. MORDELT, I. SCHWIDDE, J. BARINOFF, S. KORLACH, F. STÖBLEN, W. LICHTENEGGER, J. SEHOULI, S. KÜMMEL ( <i>Düsseldorf; Berlin; Essen, Germany</i> ) .....	2651
First Evaluation of the Joint Clinical Registry Data of Patients with Primary Ovarian Cancer at the Coordinating Tumor Center of Berlin. R. CHEKEROV, S. BRAUN, A.D. EBERT, C. HERBSTREIT, A. JAGOTA, K.D. JOHANNSMEYER, C. KRONENBERGER, J. POTENBERG, J.P. SCHARF, R. RICHTER, U. ULRICH, J. SEHOULI ( <i>Berlin, Germany</i> ) .....	2657
* Review: The Mutational Profile of Sporadic Epithelial Ovarian Carcinoma. S. KALAMANATHAN, V. BATES, R. LORD, J.A. GREEN ( <i>Liverpool; Wirral, Merseyside, UK</i> ) .....	2661
Optimizing the Clinical Management of Gynecological and Breast Cancer via Online Tumor Conferences. J.K. SCHROEDER, S. KUEMMEL, K. PIETZNER, J. HECTOR, J. SEHOULI, R. CHEKEROV ( <i>Essen; Berlin, Germany</i> ) .....	2669
Long Term Combination Treatment with Bevacizumab, Pegylated Liposomal Doxorubicin and Regional Abdominal Hyperthermia in Platinum Refractory Ovarian Cancer: A Case Report and Review of the Literature. K. PIETZNER, R.B. SCHMUCK, C. FOTOPOULOU, J. GELLERMANN, F. ISMAEEL, C.H. CHO, M. KALDEN, J. SEHOULI ( <i>Berlin; Jena; Dortmund, Germany</i> ) .....	2675
Bevacizumab in Heavily Pre-treated and Platinum Resistant Ovarian Cancer: A Retrospective Study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group. K. PIETZNER, R. RICHTER, R. CHEKEROV, E. EROL, G. OSKAY-ÖZCELIK, W. LICHTENEGGER, J. SEHOULI ( <i>Berlin, Germany</i> ) .....	2679
* Reviews (pages 2623, 2661)	